PHILADELPHIA, PA – HealthVerity, the leader in real-world data (RWD) technologies and privacy-compliant data exchange, today announced the launch of taXonomy Pathways, a groundbreaking framework that unites closed payer claims, lab results and electronic health records (EHR), including physician notes into research-ready therapeutic area-specific datasets designed to close critical evidence gaps across life sciences, payers, government and consulting partners.

Therapeutic areas from taXonomy Pathways are anchored by the nation’s largest source of closed payer claims, spanning hundreds of payers, nine years of adjudicated history and more than 300 million patients across all pay types. The acclaimed taXonomy data model synthesizes multi-payer medical and pharmacy claims and eligibility into a streamlined relational dataset that enables efficient ingestion and onboarding. Teams are able to get up to speed quickly and translate study protocols to valuable analysis . Further innovation comes from expanding beyond claims into novel patient features that are only available from lab results and EHR, including physician notes, that fundamentally enrich the patient journey.

In diabetes and obesity cohorts, repeated measures such as BMI, HbA1c, weight, blood pressure and lipid panels provide a comprehensive view of disease progression and treatment response. For heart failure, echocardiogram‑derived left‑ventricular ejection fraction and cardiovascular labs illuminate cardiac function, guideline‑directed therapy uptake and hospitalisation risk. In oncology, lab results confirm diagnosis and provide prognostic insight essential for precision medicine, while for neurology and rare diseases, structured EMR and clinical notes reveal symptom‑level detail, adverse events and real‑world outcomes that claims cannot capture.

“With taXonomy Pathways, we are simplifying the assembly of longitudinal patient journeys” said Andrew Kress, CEO of HealthVerity. “Now, researchers can seamlessly access claims, EHR, labs and clinical notes in a single, research-ready framework that accelerates time to evidence without compromising rigor, privacy or scale. This is a game-changer for real-world evidence, safety and beyond.”

taXonomy Pathways includes lab results from two leading outpatient labs, representing more than 60% of U.S. testing, including genetic assays. Lab values and collection dates align with exposure windows from medical and pharmacy claims to derive baselines and quantify treatment response. RWE and HEOR teams can track how often diagnostic tests are followed by treatment and assess test yield by payer and region, giving market access teams evidence to shape coverage policies and provider engagement.

To deepen insights further, taXonomy Pathways incorporates more than 3.6 billion de‑identified clinical notes across 340 million encounters for 43 million patients. These narrative notes capture symptoms, disease severity, imaging results, contraindications and reasons for discontinuation, giving researchers a broader view across therapeutic areas that far exceeds a claims-only approach.

Available now

taXonomy Pathways is available today. For more information, register for our webinar to see how you can close the evidence gap in your therapeutic area or schedule a meeting with our sales team.

About HealthVerity

HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry’s largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, regulatory decision-making, and public health.

Media Contact:

HealthVerity
info@healthverity.com

PHILADELPHIA, PA and SAN FRANCISCO, CA – HealthVerity, the leader in real-world data (RWD) technologies and privacy-compliant data exchange, today launched HealthVerity eXOs. This novel research analytics platform, powered by Medeloop, enables biopharma companies to leverage AI to rapidly design, iterate and generate a wide range of real-world studies and commercial insights in a fraction of the time and cost of legacy solutions. Running atop a built-in nationwide patient dataset of verified RWD, HealthVerity eXOs offers a conversational AI platform for HEOR, Medical Affairs, Commercial and beyond that delivers transparent, audit-ready insights in minutes.

HealthVerity eXOs eliminates the uncertainty leading up to drug launches for a biopharma industry that thrives on certainty. With fewer than 24% of major biopharma launches meeting sales forecasts, the industry demands an approach that can deliver better real-world evidence and strategic commercial insights from the onset.1 Growth-stage biopharma must operate on scarce capital while matching the analytic rigor of larger competitors. HealthVerity eXOs directly addresses these challenges, enabling teams to accelerate accurate evidence generation, sharpen strategies and drive to launch with confidence.

HealthVerity eXOs is built on leading agentic AI technology from Medeloop and is designed to deliver unmatched accessibility, transparency and speed. It offers team-wide access to on-demand analytics across nationwide patient data through simple, plain English prompts. Every run provides full visibility into cohort definitions, coding logic and outputs so methods are interpretable and results are defensible. Because HealthVerity eXOs delivers real world data in minutes, teams can move from question to decision faster.

“With HealthVerity eXOs, we have removed the barriers between innovators and the real-world data they need,” said Andrew Kress, CEO of HealthVerity. “For the first time, small and midsize biopharma can generate regulatory-grade evidence instantly—without sacrificing rigor or trust. HealthVerity eXOs empowers unlimited exploration, regulatory defensibility, and a seamless path from question to insight.”

Leading biopharmas confirm the advantage

Early adopters are already validating the transformational impact of HealthVerity eXOs across key user groups.

“For Commercial strategic planning and execution, tempo is everything. With HealthVerity eXOs, our team of non-coders can ask simple questions, verify the steps the conversational agent will take, and get almost immediate insights. That combination of speed and interpretability lets us calibrate assumptions, monitor uptake, and refine tactics with confidence—putting us in a position of strength.”
— Mark Booth, Head of Portfolio Strategy Rare Disease, Chiesi USA

“For RWE, high-quality credible data analyzed transparently are non-negotiable. HealthVerity eXOs has provided transparent cohort and coding logic and audit-ready outputs almost instantly, in less than an hour compared to weeks. This will enable us to accelerate our efforts, without compromising rigor.”
— Chris Pashos, Ph.D., Head of Real-World Evidence, Argenx

Partners in advancing life science evidence

HealthVerity eXOs was forged by the recently announced HealthVerity–Medeloop partnership around healthcare data analytics, featured in POLITICO. 

“Medeloop is proud to bring the power of our AI-native analytics to market via HealthVerity eXOs,” said Rene Caissie, CEO of Medeloop. “By layering Medeloop’s agentic AI on top of HealthVerity’s unmatched real-world data, we are enabling biopharma companies to harness data insights that can help them understand patient needs, bring critical treatments to patients sooner and ultimately improve patient lives.”

Available now

HealthVerity eXOs is generally available to biopharma and academic organizations spanning discovery, development, launch, and post-market activities. Register for our upcoming webinar on October 15 to see the platform in action or request a demo today.

About HealthVerity

HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry’s largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, regulatory decision-making, and public health.

Media Contact:

HealthVerity
info@healthverity.com

About Medeloop

Medeloop offers advanced, AI-native analytics platforms designed to simplify and accelerate healthcare research, enabling pharmaceutical companies, healthcare providers, and researchers to rapidly derive actionable insights from complex real-world data by simply asking a question.

Media Contact:

Medeloop
John W. Ayers, Ph.D., M.A
jayers@medeloop.ai

1. World preview 2024 – pharma’s growth boost—Ebook. (n.d.). Evaluate. Retrieved September 10, 2025, from https://www.evaluate.com/thought-leadership/world-preview-2024-report/

PHILADELPHIA, PA – HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced a major milestone with its 100th peer-reviewed publication having been published based on Verified data from HealthVerity Marketplace. This achievement underscores the growing importance of Verified RWD in powering important research across a broad range of healthcare topics, from cardiovascular disease and oncology to rare disease and the role of AI.

The milestone highlights the depth and stability of data from HealthVerity Marketplace, the nation’s largest healthcare and consumer data ecosystem. By providing access to an expansive array of accurately linked, HIPAA-compliant data types, including medical and pharmacy claims, lab results, EMR, and unstructured clinical notes, HealthVerity empowers researchers to uncover new insights into patient journeys, treatment effectiveness and health outcomes.

Crossing the century mark for scientific publications is a meaningful validation of the critical role HealthVerity plays in advancing real-world evidence. Researchers, pharmaceutical manufacturers and public healthcare agencies trust RWD from HealthVerity to be novel, reliable and licensed from known data sources, attributes that are critical for advancing science and improving patient care.

From clinical trial optimization to post-market safety monitoring, these publications illustrate the versatility of HealthVerity data in addressing today’s most intriguing healthcare questions. Research teams from top Pharma and biotech organizations have leveraged HealthVerity Marketplace to track disease prevalence and patient outcomes at true population scale, analyze treatment adherence and effectiveness across therapy classes, study rare disease patient populations with unmatched precision and stability, and support regulatory-grade evidence generation for FDA review and beyond.

“The sheer volume of published work being achieved with HealthVerity Verified data is a validation of the quality and utility of the sources being provided as well as the ease by which life science and public health study teams can assemble the necessary data,” said Andrew Kress, CEO of HealthVerity. 

A complete list of current publications can be viewed here: https://healthverity.com/resources/publications/

About HealthVerity

HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry’s largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, and regulatory decision-making. healthverity.com

HealthVerity Contact:

info@healthverity.com

PHILADELPHIA, PA – HealthVerity, the leader in privacy-protecting technologies and the nation’s largest verified healthcare and consumer data ecosystem, today announced the launch of HealthVerity Notes, a modular, de-identified dataset built from over 2.5 billion unstructured clinical EHR notes that employs novel methodologies to preserve the full note. This approach adds vital context to real-world data strategies across life sciences research, commercial pharma and analytics use cases.

Building on a commitment to verified, research-ready data, HealthVerity Notes introduces a new dimension of patient understanding by unlocking free-text documentation from clinical encounters including insights from physician observations and symptom descriptions to disease progression and therapeutic response. Delivered with modular access and accurately linked by HealthVerity IDs (HVIDs), HealthVerity Notes is now available as an integral part of the nation’s largest data ecosystem. The underlying de-identification technology can also be leveraged by data providers to commercialize a wider range of free-text documents.

“With HealthVerity Notes, we’re turning the unstructured into the actionable,” said Andrew Kress, CEO at HealthVerity. “This launch marks an important new capability in our mission to help life sciences organizations unlock deeper insights from real-world data, while preserving patient privacy and ensuring interoperability across datasets.”

By preserving the full text of the original clinical documentation, HealthVerity Notes supports downstream use of natural language processing (NLP), offering linguistically intact and context-rich documentation that complements structured claims, EHR, and lab data. Whether identifying undiagnosed symptoms, tracing adverse events, or capturing disease trajectory, HealthVerity Notes enables more complete, narrative-driven analytics.

HealthVerity Notes is now available with use cases spanning clinical development, HEOR, pharmacovigilance, commercial analytics and patient journey analysis.

To learn more, visit www.healthverity.com/notes or contact info@healthverity.com.

About HealthVerity

HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry’s largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, and regulatory decision-making. healthverity.com

HealthVerity Contact:

info@healthverity.com

PHILADELPHIA, PA — HealthVerity, the leader in synchronizing transformational technologies and real-world data (RWD) to advance the science, today raised the bar by announcing the introduction of HealthVerity taXOnomy, the nation’s most expansive, exacting, and efficient closed (X) and open (O) claims dataset to power pharmaceutical research and sophisticated commercial strategies. This integrated data solution can be leveraged for a wider variety of use cases throughout the drug lifecycle – from accelerating commercial insights and strategies to finding ideal clinical trial sites, recruiting optimal patients and developing real-world evidence – providing unmatched clarity into patient journeys with the speed and flexibility that is required to meet today’s market challenges.

With the growing need for more complex and personalized medications, it is vital to have the most comprehensive view of the patient journey. The expansive taXOnomy dataset, built on the company’s success with its closed claims-focused taXonomy solution, integrates both closed and open claims. It encompasses hundreds of millions of patient lives to span the payer and physician landscape in a single view, often uncovering 25% – 65% more patients from the medical benefit than legacy solutions. Furthermore, taXOnomy is designed to be HIPAA-compliant and fully interoperable with lab results, electronic medical records, and hospital chargemaster data to fill key gaps in care and to deliver additional signal for diagnoses, procedures, lab results, and treatments.

HealthVerity taXOnomy meets the pharma industry’s exacting standards with an expertly curated data model that yields more accurate and comprehensive outcomes. And where legacy data solutions are plagued by time consuming HIPAA certifications, inconsistent data updates and reporting, and a lack of interoperability with novel data sources, HealthVerity taXOnomy offers a privacy-protected, HIPAA-certified, and research-ready dataset that is fully interoperable with the nation’s largest healthcare and consumer data ecosystem. The HealthVerity approach continually supports new payers and is updated daily to provide the most efficient reporting for mission-critical decision making.

“At HealthVerity, we are dedicated to bringing the life sciences industry the most robust data solutions in a frictionless manner, fundamentally enabling better patient outcomes,” said Andrew Kress, CEO of HealthVerity. “Our life sciences clients have been advantaged by our groundbreaking closed claims dataset, taXonomy, and have been asking us to assemble the unparalleled coverage, accuracy and interoperability that only HealthVerity taXOnomy can deliver for challenges across the drug development and treatment lifecycle.”

To learn more, register for our webinar on Wednesday, September 18 at 12:00 p.m. ET, where we will reveal key details about HealthVerity taXOnomy.

About HealthVerity

HealthVerity synchronizes transformational technologies with the nation’s largest healthcare and consumer data ecosystem to power previously unattainable outcomes and fundamentally advance the science. We offer a comprehensive, yet flexible approach, based on the foundational elements of Identity, Privacy, Governance and Exchange (IPGE), that synchronizes unparalleled Identity management with built-in Privacy compliance and Governance, providing the ability to discover and Exchange a near limitless combination of data at a record pace. Together with our partners in life sciences, government and insurance, we are Synchronizing the Science. To learn more about HealthVerity, visit healthverity.com.

For more information, contact:

HealthVerity
info@healthverity.com